Clinical Trials
3 trialsNCT07015242 2026-03-24
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT00003056 2021-05-06
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Takeda
Phase 3 Terminated
NCT00517699 2014-08-08
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Hoffmann-La Roche
Phase 2 Terminated